Bristol-myers Squibb Compnay

Domantis Limited

Cytomx Therapeutics, Inc.

The Rockefeller University

Aaron Paul Yamniuk

Guodong Chen

Suzanne J Suchard

Bryan C Barnhart

Steven Grant

James William Bryson

James K Tamura

Anish Suri

Stanley Richard Krystek, Jr

Martin J Corbett

Alan J Korman

Mohan Srinivasan

Nils Lonberg

Ginger Chao Rakestraw

Karla Ann Henning

Steven G Nadler

Olga Ignatovich

Robert P Rehfuss

Haichun Huang

Richard Y Huang

Dasa Lipovsek

Maria N Jure-Kunkel

Brigitte Devaux

Sharon T Cload

Brenda L Stevens

Linda Engle

Alexander T Kozhich

Joanna F Swain

Malavi Madireddi

Michael L Gosselin

Mary Struthers

Mark J Selby

James William West

Arvind Rajpal

Michelle Minhua Han

Scott Ronald Brodeur

Ekaterina G Deyanova

Jeffrey V Ravetch

Kent B Thudium

Han Chang

Changyu Wang

Mark F Maurer

Xi-Tao Wang

Akbar Nayeem

Indrani Chakraborty

Huiming Li

Jochem Gokemeijer

Thomas D Kempe

Philip Drew

Laura Price

Ming Lei

Liang Schweizer

Sandra V Hatcher

Achal Mukundrao Pashine

Richard Yu-Cheng Huang

Stephen Michael Carl

Wenjun Zhao

Hui Wei

John S Sack

Shannon Lee Okada

Steven Sheriff

Michael Quigley

Xiang Shao

Vidhyashankar Ramamurthy

Emanuela Sega

Angela Goodenough

Joseph E Myers, Jr

Pingping Zhang

Priyanka Apurva Madia

Derek A Holmes

Lin Hui Su

Yun Wang

Alfred Robert Langish

Hong Shen

Susan Chien-Szu Wong

Hadia Lemar

Marie-Michelle Navarro Garcia

Christina Maria Milburn

Patrick Guirnalda

Stanley Krystek

Rony Dahan

Zhehong Cai

Zheng Yang

Christine Huang

Yan Feng

Praveen Aanur

Joanna Swain

Stanley Richard Krystek

Joseph E Myers

Maria Rodriguez

Stanley R Krystek

James Tamura

Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40 and comprise improved heavy and light chain variable regions that impart improved yield and reduced aggregation. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.

Anti-CD40 antibodies and uses thereof

Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TREM-1 signaling, wherein the antibodies do not bind to one or more FcγRs and do not induce the myeloid cells to produce inflammatory cytokines. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.

Nucleic acids encoding anti-TREM-1 antibodies

Anti-TREM-1 antibodies and uses thereof

Provided herein are antibodies that bind to the alpha subunit of an IL-7 receptor (IL-7Rα). Also provided are uses of these antibodies in therapeutic applications, such as treatment of inflammatory diseases. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain regions of the antibodies, and vectors comprising the polynucleotides.

Antibodies against IL-7R alpha subunit and uses thereof

The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.

Fibronectin based scaffold domain proteins that bind to myostatin

Provided herein are polypeptides comprising a modified fibronectin type III (Fn3) domain, wherein the amino acid corresponding to residue 58 of SEQ ID NO: 1 is mutated, and wherein the solubility is enhanced relative to the solubility of a Fn3 domain in which the amino acid corresponding to residue 58 of SEQ ID NO: 1 is not mutated. Also provided are libraries comprising a plurality of the polypeptides and a method for identifying a polypeptide that binds to a target.

Fibronectin type III domain proteins with enhanced solubility

The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.

Antibodies against CD73 and uses thereof

The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.

Antagonistic CD40 monoclonal antibodies and uses thereof

Antagonistic CD40 monoclonal antibodies and uses in treating immune responses

The disclosure provides for antibodies that bind CD40, including a humanized antibody and a chimeric antibody with different Fc domains. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.

Antagonistic anti-CD40 antibodies and methods of antagonizing CD40 activity

Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR)

Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single Vor Vdomain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.

Antibody polypeptides that antagonize CD40L

Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TREM-1 signaling, wherein the antibodies do not bind to one or more Fc&#x3b3;Rs and do not induce the myeloid cells to produce inflammatory cytokines. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.

Antibody polypeptides that specifically bind a novel epitope of human CD40 are provided. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides are useful in the treatment of diseases involving CD40 activation, such as autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single Vor Vdomain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA).

Methods of treating immune diseases by administering antibody polypeptides that antagonize CD40

Growing community of inventors

Lawrenceville, NJ, United States of America

Aaron Paul Yamniuk